Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
Open accessAbstract
OBJECTIVE: To assess expert consensus on barriers and facilitators for long-acting injectable antipsychotic (LAI) use and provide clinical recommendations on issues where clinical evidence is lacking, including identifying appropriate clinical situations for LAI use. METHODS: A 50-question survey comprising 916 response options was distributed to 42 research experts and high prescribers with extensive LAI experience. Respondents rated options on relative appropriateness/importance using a 9-point scale. Consensus was determined using chi-square test of score distributions. Mean (standard deviation) ratings were calculated. Responses to 29 questions (577 options) relating to appropriate patients and clinical scenarios for LAI use are reported. RESULTS: Recommendations aligned with research on risk factors for nonadherence and poor outcomes for patients with schizophrenia/schizoaffective or bipolar disorder. Findings suggested, contrary to general practice patterns, that LAI use may be appropriate earlier in the disease course and in younger patients. Results for bipolar disorder were similar to those for schizophrenia but with less consensus. Numerous facilitators of LAI prescribing were considered important, particularly that LAIs may reduce relapses and improve outcomes. CONCLUSION: Findings support wider use of LAIs in patients with schizophrenia/schizoaffective and bipolar disorders beyond the setting of poor adherence and earlier use in the disease course.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Europe, only 40% of clinicians would use LAIs for treating first-episode psychosis, and a large portion tend to use LAIs only in patients with long-term disease and poor compliance.
“In Europe only 40% of clinicians would use LAIs for treating first-episode psychosis [32], while a large portion of them tend to use LAIs only in the case of patients with long-term disease and poor compliance [33, 34].”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428 · see citing works
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1× · see citing works
“50% have been reported.(20,21) Poor adherence with oral medication has been cited as a primary modifiable reason for poor outcomes(22) and for prescribing LAIs.”
BackgroundYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQUEEN, G. M., McIntyre, R. S., Sharma, V., et al. (2012) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,209 · see citing works
A Method for the Detailed Assessment of the Appropriateness of Medical Technologies
Brook, R. H., Chassin, M. R., Fink, A., Solomon, D. H., Kosecoff, J., & Park, R. E. (1986) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300002774 · Cited by 762 · see citing works
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423363.45859 · Cited by 733 · see citing works
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520 · see citing works
Self-citationKishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08440 · Cited by 427 · cited 1× · see citing works
“11,12 Furthermore, meta-analyses of mirror-image studies 13 and cohort studies, 14 which may include more real-world patients than RCTs, 15 have demonstrated a lower risk of all-cause discontinuation and frequency of hospitalizations with LAIs versus oral antipsychotics.”
BackgroundSelf-citationKishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395 · see citing works
Self-citationThe Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15032su1 · Cited by 372 · see citing works
Self-citationAdherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients
García, S., Martínez‐Cengotitabengoa, M., López-Zurbano, S., Zorrilla, E. P., López‐Mahía, P., Vieta, E., & González-Pinto, A. M. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000523 · Cited by 363 · see citing works
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works
Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0270 · Cited by 262 · see citing works
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257 · see citing works
Self-citationKane, J. M., Leucht, S., Carpenter, D. P., & Docherty, J. P. (2003) · PubMed · Cited by 234 · see citing works
Self-citationKaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201 · see citing works
Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-340 · Cited by 188 · cited 3× · see citing works
“16,18,36 Although disadvantages of LAIs include longer time to achieve steady state and less flexibility with dose adjustments, 1 LAIs may also simplify the treatment regimen and reduce patient medication-taking burden.”
BackgroundMethodKishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186 · see citing works
Self-citationDeterminants of adherence to treatment in bipolar disorder: A comprehensive review
Leclerc, E., Mansur, R. B., & Brietzke, E. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.036 · Cited by 171 · see citing works
Attitudes of Psychiatrists Toward Antipsychotic Depot Medication
Heres, S., Hamann, J., Kissling, W., & Leucht, S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1216 · Cited by 152 · see citing works
Clinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 147 · see citing works
Self-citationPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner, A., Aadamsoo, K., Altamura, A. C., Franco, M., Gorwood, P., Neznanov, N. G., Schronen, J., Ucok, A., Zink, M., Janik, A., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.015 · Cited by 145 · cited 1× · see citing works
“Although some data show comparable outcomes between oral antipsychotics and LAIs,(8,9) several randomized controlled trials (RCTs) in patients with schizophrenia demonstrated a significant delay and reduction in relapse with LAIs compared with oral antipsychotics, particularly in patients with early-phase or first-epi…”
ResultJaeger, M., & Wulf Rössler, A. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.11.003 · Cited by 144 · see citing works
Olivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., & Lam, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.12.002 · Cited by 141 · see citing works
The case for long‐acting antipsychotic agents in the post‐CATIE era
Nasrallah, H. A. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00982.x · Cited by 135 · see citing works
Byerly, M., Thompson, A. K., Carmody, T. J., Bugno, R., Erwin, T., Kashner, M. T., & Rush, A. J. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.6.844 · Cited by 134 · see citing works
Self-citationKane, J. M., Kishimoto, T., & Correll, C. U. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.01.012 · Cited by 131 · see citing works
Self-citationPatel, M., Haddad, P. M., Chaudhry, I. B., McLoughlin, S., & David, A. S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109104882 · Cited by 115 · see citing works
Antipsychotic long-acting injections: Prescribing practice in the UK
Barnes, T. R. E., Shingleton‐Smith, A., & Paton, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s37 · Cited by 114 · see citing works
Bartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., DeTore, N. R., Altshuler, L. L., Mintz, J., Ventura, J., Casaus, L. R., Luo, J. S., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.029 · Cited by 95 · see citing works
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Parellada, E., & Bioque, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0350-7 · Cited by 89 · see citing works
Bartzokis, G., Lu, P. H., Raven, E. P., Amar, C. P., DeTore, N. R., Couvrette, A., Mintz, J., Ventura, J., Casaus, L. R., Luo, J. S., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.036 · Cited by 81 · see citing works
Treatment of schizophrenia 1999. The expert consensus guideline series.
(1999) · PubMed · Cited by 71 · see citing works
Rauch, A.-S., & Fleischhacker, W. W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0083-9 · Cited by 64 · see citing works
Weiden, P. J., Preskorn, S., Fahnestock, P. A., Carpenter, D. P., ROSS, R. W., & Docherty, J. P. (2007) · PubMed · Cited by 63 · see citing works
Self-citationOfford, S., Wong, B., Mirski, D., Baker, R. A., & Lin, J. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.751025 · Cited by 62 · see citing works
Stephenson, J. J., Tuncelli, O., Gu, T., Eisenberg, D. F., Panish, J. M., Crivera, C., & Dirani, R. D. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02918.x · Cited by 59 · see citing works
Haddad, P., Kishimoto, T., Correll, C., & Kane, J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000160 · Cited by 58 · see citing works
Self-citationLong-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder
Gigante, A. D., Lafer, B., & Yatham, L. N. (2012) · CNS Drugs · doi:10.2165/11631310-000000000-00000 · Cited by 58 · see citing works
Consensus methods in practice guideline development: a review and description of a new method.
Kahn, D. A., Docherty, J. P., Carpenter, D., & Frances, A. (1997) · PubMed · Cited by 55 · see citing works
The Challenge of Offering Long-Acting Antipsychotic Therapies
Weiden, P. J., Roma, R. S., Velligan, D. I., Alphs, L. D., DiChiara, M., & Davidson, B. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08946 · Cited by 55 · see citing works
Geerts, P., Martinez, G., & Schreiner, A. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-58 · Cited by 48 · see citing works
Chou, Y. H., Chu, P.-C., Wu, S.-W., Lee, J.-C., Lee, Y., Sun, I.-W., Chang, C., Huang, C.-L., Liu, I., Tsai, C.-F., et al. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.2.121 · Cited by 40 · see citing works
Sajatovic, M., ROSS, R. W., Legacy, S. N., Byerly, M., Kane, J. M., DiBiasi, F., Fitzgerald, H. M., & Correll, C. U. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167485 · Cited by 38 · see citing works
Self-citationAlphs, L. D., Mao, L., Starr, H. L., & Benson, C. J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.12.012 · Cited by 32 · see citing works
History and Therapeutic Rationale of Long Acting Antipsychotics
Risio, A. D., & Lang, A. P. (2014) · Current Clinical Pharmacology · doi:10.2174/15748847113089990057 · Cited by 27 · see citing works
Peters, L., Krogmann, A., von Hardenberg, L., Bödeker, K., Nöhles, V., & Correll, C. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1114-0 · Cited by 25 · see citing works
Self-citationGuidelines for the use of second-generation long-acting antipsychotics
Jarema, M., Wichniak, A., Dudek, D., Samochowiec, J., Bieńkowski, P., & RYBAKOWSKI, J. K. (2015) · Psychiatria Polska · doi:10.12740/pp/39370 · Cited by 14 · see citing works
Sajatovic, M., DiBiasi, F., & Legacy, S. N. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s139557 · Cited by 12 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Fiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110 · see citing works
Kane, J., Mcevoy, J., Correll, C., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 74 · see citing works
Self-citationGuinart, D., Misawa, F., Rubio, J. M., Pereira, J., de Filippis, R., Gastaldon, C., Kane, J. M., & Correll, C. U. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13359 · Cited by 57 · see citing works
Self-citationLindenmayer, J., Glick, I. D., Talreja, H., & Underriner, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001225 · Cited by 53 · see citing works
Guinart, D., Taipale, H. T., Rubio, J. M., Tanskanen, A. J., Correll, C. U., Tiihonen, J., & Kane, J. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab062 · Cited by 43 · see citing works
Self-citationAbdel‐Baki, A., Thibault, D., Medrano, S., Stip, É., Ladouceur, M., Tahir, M. R., & Potvin, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12826 · Cited by 39 · see citing works
Højlund, M., & Correll, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2228686 · Cited by 36 · see citing works
Self-citationCitrome, L., Belcher, E. D., Stacy, S., Suett, M., Mychaskiw, M. A., & Salinas, G. D. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s326299 · Cited by 29 · see citing works
Arango, C., Fagiolini, A. M., Gorwood, P. A. P. M., Kane, J. M., Diaz-Mendoza, S., Sahota, N., & Correll, C. U. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04928-0 · Cited by 27 · see citing works
Self-citationPeters, L., Krogmann, A., von Hardenberg, L., Bödeker, K., Nöhles, V., & Correll, C. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1114-0 · Cited by 25 · see citing works
Self-citationReymann, S., Schoretsanitis, G., Egger, S., Mohonko, A., Kirschner, M., Vetter, S., Homan, P., Seifritz, E., & Burrer, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030441 · Cited by 23 · see citing works
Kane, J. M., Chen, A., Lim, S., Mychaskiw, M. A., Tian, M., Wang, Y., Suett, M., & Rubio, J. M. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000452 · Cited by 20 · see citing works
Self-citationFitzgerald, H. M., Shepherd, J., Bailey, H. M. L., Berry, M., Wright, J., & Chen, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s330936 · Cited by 17 · see citing works
Self-citationKeenan, A., Lin, D., Shepherd, J., Bailey, H. M. L., Benson, C. J., & Meakin, S. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03846-x · Cited by 16 · see citing works
Velligan, D. I., Salinas, G. D., Belcher, E. D., Franzenburg, K. R., Suett, M., Thompson, S., & Hansen, R. T. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06565-1 · Cited by 15 · see citing works
Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics
Grover, S., Sahoo, S., & Mehra, A. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001109 · Cited by 15 · see citing works
Miron, A. A., Petric, P. S., Teodorescu, A., Ifteni, P. I., Chele, G. E., & Szalontay, A. S. (2023) · Brain Sciences · doi:10.3390/brainsci13020173 · Cited by 13 · see citing works
Kane, J. M., Agid, O., Castle, D. J., Citrome, L., Fagiolini, A., Kishimoto, T., Larrauri, C. A., Leucht, S., Rubio, J. M., Sajatovic, M., et al. (2025) · Neurological Therapeutics · doi:10.1007/s40120-025-00838-3 · Cited by 14 · see citing works
Self-citationBlack, R. M., Hughes, T. D., Ma, F., Hudzik, A., Shepherd, G., Ferreri, S. P., & Ozawa, S. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.08.006 · Cited by 11 · see citing works
Correll, C. U., Arango, C., Fagiolini, A. M., Giordano, G. M., Leucht, S., & de Pablo, G. S. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s459450 · Cited by 10 · see citing works
Self-citationCorrell, C. (2025) · CNS Spectrums · doi:10.1017/s1092852925100503 · Cited by 10 · see citing works
Self-citationAripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals
Sommi, R. W., Rege, B., Wehr, A. Y., FALDU, S. P., Du, Y., & Weiden, P. J. (2020) · CNS Spectrums · doi:10.1017/s1092852920002072 · Cited by 9 · see citing works
Tatini, L., D’Anna, G., Pietrini, F., Calligaris, E., Ballerini, A., & Ricca, V. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000359 · Cited by 9 · see citing works
Liu, Y., Patterson, M. E., Sahil, S., & Stoner, S. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140969 · Cited by 8 · see citing works
Correll, C. U., Rubio, J. M., Citrome, L., Mychaskiw, M. A., Thompson, S., Franzenburg, K. R., Suett, M., Kotak, S. V., & Kane, J. M. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s477674 · Cited by 8 · see citing works
Self-citationAguglia, A., Fusar‐Poli, L., Amerio, A., Placenti, V., Concerto, C., Martinotti, G., Carrà, G., Bartoli, F., D’Agostino, A., Serafini, G., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.784366 · Cited by 8 · see citing works
Walling, D. P., Dong, Y., Litman, R. E., Wang, W., Liu, C., Tai, J., Liu, P., Shi, Y., Liu, W., Fu, F., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6143 · Cited by 6 · see citing works
Kappi, A. A., Wang, T., Abufarsakh, B., & Okoli, C. T. C. (2024) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903241279605 · Cited by 5 · see citing works
Velligan, D. I., Salinas, G. D., Belcher, E. D., Franzenburg, K. R., Suett, M., Thompson, S., & Hansen, R. T. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaf001 · Cited by 5 · see citing works
Pungor, K., Bozikas, V. P., Emsley, R. A., Llorca, P., Gopal, S., Mathews, M., Wooller, A., & Bergmans, P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981500 · Cited by 5 · see citing works
The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia
Harrison, S. J., Antunes, J., Knight, K., Johnston, K., Mehawej, J., Sanchez, P., & Correll, C. U. (2026) · CNS Drugs · doi:10.1007/s40263-026-01294-9 · Cited by 3 · see citing works
Self-citationLin, T.-C., Lin, C., & Chiu, H.-P. (2025) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_9_25 · Cited by 3 · see citing works
Förster, S., Gancz, N. N., Gaither, M. L., Haas, G. L., Starver, K. D., & Steinhauer, S. R. (2022) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000673 · Cited by 3 · see citing works
Wagner, E. M., Katyal, S., Lee, I. O., Tasnim, S., Wadia, H. E., Mortazavi, M., García-Carmona, J. A., Hasan, A., Colman, I., Taipale, H. T., et al. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251412576 · Cited by 2 · see citing works
Self-citationRoy, M., Therrien, F., Boucher, M., & Oluboka, O. J. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06240-x · Cited by 2 · see citing works
Patel, R., Liman, C., Oyesanya, M., Ker, S., Jayaraman, A., Franzenburg, K. R., Hansen, R. T., Philbin, M. J., & Thompson, S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092216 · Cited by 2 · see citing works
Clinical Applications of Long Acting Injectables: Systemic and Local Drug Delivery
Witika, B. A., Poka, M., Makoni, P. A., Ramazani, F., & Nkanga, C. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-72302-5_7 · Cited by 1 · see citing works
Alphs, L. D., Baker, P. C., Brown, B., Fu, D., Turkoz, I., & Nuechterlein, K. H. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.07.015 · Cited by 1 · see citing works
Lewis, L. M., & Rodgers, J. (2022) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903221075651
Keenan, A., Lin, D., Shepherd, J., Bailey, H., Benson, C. J., & Meakin, S. (2022) · Figshare · doi:10.6084/m9.figshare.19381101
Keenan, A., Lin, D., Shepherd, J., Bailey, H., Benson, C. J., & Meakin, S. (2022) · Figshare · doi:10.6084/m9.figshare.19381095
Keenan, A., Lin, D., Shepherd, J., Bailey, H., Benson, C. J., & Meakin, S. (2022) · Figshare · doi:10.6084/m9.figshare.19381098
Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview
Sahoo, S., Sreeraj, V. S., Gopalakrishnan, G., Ameen, S., Cholera, R. M., Venkatasubramanian, G., & Malhotra, S. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1341_25
Sharma, J., Ahluwalia, I., Desai, D., Gadhvi, J., Chaudhury, S., & Patel, M. K. (2026) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_779_25
- Authors
- Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M.
- Affiliations
- University Hospitals of Cleveland (US)
- Otsuka (United States) (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Lundbeck (United States) (US)
- Montana State University (US)
- Corresponding author
- Sajatovic, Martha
- ORCID
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2018-06
- Volume
- Volume 14
- Pages
- 1463-1474
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5997124
- OpenAlex
- W2807486965
- Cited by
- 44
- References
- 48
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 5 · 2022: 10 · 2021: 6 · 2020: 4 · 2019: 3
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Scholarly Commons @ Case Western Reserve University (submittedVersion, cc-by-nc)
- Funders
- Otsuka Pharmaceutical
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- long-acting injectable antipsychotics, schizophrenia, schizoaffective disorder, bipolar disorder, medication adherence, early treatment initiation, relapse prevention, expert consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
